AZD9574 is an experimental medication being studied for its potential to treat advanced solid tumors. It is being tested to see how safe and tolerable it is when used alone and in combination with other cancer treatments. Researchers are also looking at how the body processes this medication and its initial effectiveness in fighting cancer.

Anti-cancer Agents are medications that are used in combination with AZD9574 in this study. These agents are designed to help fight cancer by targeting and killing cancer cells or stopping them from growing. The study aims to see how well these agents work together with AZD9574 to treat advanced malignancies.

IDH-mutant glioma – This is a type of brain tumor characterized by mutations in the isocitrate dehydrogenase (IDH) gene. These mutations lead to abnormal cell growth in the brain. Gliomas can vary in their aggressiveness, with some growing slowly and others more rapidly. The presence of IDH mutations often indicates a distinct biological behavior compared to gliomas without these mutations. Over time, these tumors can cause symptoms such as headaches, seizures, and neurological deficits depending on their location in the brain.

HER2-negative breast cancer – This form of breast cancer does not have an overexpression of the HER2 protein, which is involved in cell growth. It can be either hormone receptor-positive or triple-negative, affecting treatment options and disease progression. HER2-negative breast cancer can spread to other parts of the body, leading to advanced or relapsed stages. The progression of the disease can vary widely among individuals, with some experiencing slow growth and others more rapid advancement.

Ovarian cancer – This cancer originates in the ovaries and is often detected at an advanced stage due to subtle early symptoms. It can spread to the pelvis and abdomen, leading to more severe symptoms as it progresses. The disease is characterized by the growth of abnormal cells that can invade nearby tissues. Over time, ovarian cancer can cause symptoms such as bloating, pelvic pain, and changes in bowel habits.

Prostate cancer – This is a common cancer in men, originating in the prostate gland. It often grows slowly and may not cause significant symptoms initially. However, as it progresses, it can lead to urinary difficulties, pelvic discomfort, and bone pain if it spreads. The disease can vary in its aggressiveness, with some forms remaining localized and others spreading to other parts of the body.

Pancreatic cancer – This cancer begins in the tissues of the pancreas, an organ involved in digestion and blood sugar regulation. It is often diagnosed at an advanced stage due to a lack of early symptoms. As it progresses, pancreatic cancer can cause abdominal pain, weight loss, and jaundice. The disease is known for its aggressive nature and potential to spread quickly to nearby organs.

BRCA1/BRCA2 mutation-associated cancers – These genetic mutations increase the risk of developing certain cancers, including breast, ovarian, prostate, and pancreatic cancers. The mutations impair the body’s ability to repair DNA damage, leading to increased cancer risk. Cancers associated with these mutations can vary in their progression and may require specific management strategies. Over time, they can lead to symptoms related to the specific type of cancer they cause.